(Q44177579)

English

A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma

scientific article published on 13 February 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

David Cunningham

3

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Josep Tabernero Caturla

9

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

author name string

A C Roy

1

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

S R Park

2

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Y K Kang

4

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Y Chao

5

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

L T Chen

6

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

C Rees

7

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

H Y Lim

8

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

F J Ramos

10

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

M Kujundzic

11

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

M B Cardic

12

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

C G Yeh

13

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

A de Gramont

14

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

publication date

13 February 2013

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

24

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

1567-1573

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT002

21 January 2018

Is there a role for second-line chemotherapy in advanced gastric cancer?

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT002

21 January 2018

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT002

21 January 2018

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT002

21 January 2018

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT002

21 January 2018

Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT002

21 January 2018

Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT002

21 January 2018

Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT002

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT002

21 January 2018

Clinical pharmacokinetics of irinotecan

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT002

21 January 2018

Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT002

21 January 2018

Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT002

21 January 2018

Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT002

21 January 2018

Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT002

21 January 2018

UGT1A1 Polymorphism Can Predict Hematologic Toxicity in Patients Treated with Irinotecan

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT002

21 January 2018

Identifiers

10.1093/ANNONC/MDT002

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44177579&oldid=2108299577"